Lerdelimumab: Difference between revisions
Content deleted Content added
Updating {{infobox_drug}} (changes to verified fields - updated 'ChemSpiderID_Ref') per Chem/infobox_drug validation (report errors or bugs) |
Citation bot (talk | contribs) m Add: pmid, author pars. 1-1. Removed parameters. | You can use this bot yourself. Report bugs here. | Headbomb |
||
| Line 38: | Line 38: | ||
| molecular_weight = |
| molecular_weight = |
||
}} |
}} |
||
'''Lerdelimumab''' ('''CAT-152''', intended trade name '''Trabio''') is a [[human]] [[monoclonal antibody]] and an [[immunosuppressive drug]] developed to reduce scarring after [[Glaucoma surgery|glaucoma drainage surgery]].<ref>{{cite journal|title=Lerdelimumab: 6B1, Anti-TGF-Beta-2 Monoclonal Antibody|date=1 February 2002|journal=Drugs in R&D |
'''Lerdelimumab''' ('''CAT-152''', intended trade name '''Trabio''') is a [[human]] [[monoclonal antibody]] and an [[immunosuppressive drug]] developed to reduce scarring after [[Glaucoma surgery|glaucoma drainage surgery]].<ref>{{cite journal|title=Lerdelimumab: 6B1, Anti-TGF-Beta-2 Monoclonal Antibody|date=1 February 2002|journal=Drugs in R&D|volume=3|issue=2|pages=106–108|url=http://www.ingentaconnect.com/content/adis/rdd/2002/00000003/00000002/art00006|doi=10.2165/00126839-200203020-00006|pmid=12001808|last1=&Na}}</ref> Development was stopped in late 2005 after unsuccessful trial results.<ref>{{cite web|url=http://goliath.ecnext.com/coms2/gi_0199-3895591/CAT-abandons-Trabio-after-second.html |title=CAT abandons Trabio after second clinical trial failure. | Goliath Business News |publisher=Goliath.ecnext.com |date=2005-03-28 |accessdate=2010-05-12}}</ref> |
||
==References== |
==References== |
||
Revision as of 05:29, 29 January 2019
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | TGF beta 2 |
| Clinical data | |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
  (what is this?) (verify) | |
Lerdelimumab (CAT-152, intended trade name Trabio) is a human monoclonal antibody and an immunosuppressive drug developed to reduce scarring after glaucoma drainage surgery.[1] Development was stopped in late 2005 after unsuccessful trial results.[2]
References
- ^ &Na (1 February 2002). "Lerdelimumab: 6B1, Anti-TGF-Beta-2 Monoclonal Antibody". Drugs in R&D. 3 (2): 106–108. doi:10.2165/00126839-200203020-00006. PMID 12001808.
- ^ "CAT abandons Trabio after second clinical trial failure. | Goliath Business News". Goliath.ecnext.com. 2005-03-28. Retrieved 2010-05-12.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |